Tiny patients, big questions: how much painkiller reaches the blood?
NCT ID NCT02860091
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how much of the pain medicine ropivacaine gets into the blood of infants and toddlers (0-4 years old) who received a nerve block for pain after chest surgery. The goal was to check if the levels were safe. The study was stopped early and included 26 children.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ropivacaine (Naropin)
- What this could lead to
- If successful, this could help doctors understand safe dosing of ropivacaine for pain control in very young children after chest surgery.
- What could go wrong
- This was a small, early study that was terminated before completion, so results are limited. It only measured drug levels, not whether the pain relief was effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ATRESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Children"S Hospital
Boston, Massachusetts, 02118, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a single nerve block slash opioid use in Children's elbow surgery?
- Can a simple pill speed up knee replacement recovery?
- A pinprick test may forecast severe pain after C-Section
- Smartphone video may read pain in a Patient's face
- Which nerve drug wins the battle against Post-Surgical knee pain?
- Could a VR headset replace pills for surgery anxiety?